Johnson D A, Breen M
Acta Psychiatr Scand. 1979 May;59(5):525-8. doi: 10.1111/j.1600-0447.1979.tb00252.x.
A prospective study of schizophrenic patients prescribed injectable depot neuroleptic drugs as maintenance therapy showed a clinically significant weight gain in 55% of patients. No significant difference was shown between flupenthixol decanoate and fluphenazine decanoate, nor was a clinically meaningful relationship shown with dose, or the use of anti-parkinsonian drugs. The weight gain continued for at least 2 years following a mental state relapse. It is suggested that the monitoring of weight and giving of appropriate advice on diet are two essential in maintenance therapy of chronic schizophrenia.
一项针对使用长效注射抗精神病药物作为维持治疗的精神分裂症患者的前瞻性研究显示，55%的患者出现了具有临床意义的体重增加。癸酸氟哌噻吨和癸酸氟奋乃静之间未显示出显著差异，与剂量或抗帕金森药物的使用也未显示出具有临床意义的关系。在精神状态复发后，体重增加持续了至少2年。建议在慢性精神分裂症的维持治疗中，监测体重并提供适当的饮食建议是两个必不可少的方面。
